Landscape Capital Management L.L.C. Makes New $1.02 Million Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Landscape Capital Management L.L.C. acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 25,435 shares of the company's stock, valued at approximately $1,019,000.

Several other large investors also recently made changes to their positions in the stock. Mather Group LLC. lifted its holdings in Ionis Pharmaceuticals by 35.8% during the 2nd quarter. Mather Group LLC. now owns 911 shares of the company's stock valued at $39,000 after purchasing an additional 240 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Ionis Pharmaceuticals by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company's stock worth $363,000 after buying an additional 261 shares during the period. Nicollet Investment Management Inc. increased its position in Ionis Pharmaceuticals by 1.5% during the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock worth $817,000 after buying an additional 294 shares during the period. Amalgamated Bank increased its position in Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company's stock worth $399,000 after buying an additional 300 shares during the period. Finally, GAMMA Investing LLC increased its position in Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company's stock worth $27,000 after buying an additional 303 shares during the period. Institutional investors and hedge funds own 93.86% of the company's stock.

Analysts Set New Price Targets

IONS has been the topic of several recent research reports. Barclays increased their price objective on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the stock an "equal weight" rating in a research report on Friday, August 2nd. Wells Fargo & Company decreased their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Guggenheim decreased their target price on Ionis Pharmaceuticals from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, October 9th. Finally, Piper Sandler cut their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $60.65.

Ionis Pharmaceuticals Stock Up 0.2 %

Ionis Pharmaceuticals stock traded up $0.07 during trading on Friday, hitting $34.01. 2,422,690 shares of the company were exchanged, compared to its average volume of 1,282,095. The business's 50 day moving average is $38.70 and its 200 day moving average is $42.47. Ionis Pharmaceuticals, Inc. has a 52 week low of $33.33 and a 52 week high of $54.44. The company has a market capitalization of $5.37 billion, a P/E ratio of -13.94 and a beta of 0.39. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86.

Insiders Place Their Bets

In other news, EVP Eric Swayze sold 1,194 shares of the company's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now owns 33,713 shares of the company's stock, valued at $1,278,396.96. This represents a 3.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brett P. Monia sold 6,630 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total value of $252,271.50. Following the transaction, the chief executive officer now directly owns 167,393 shares in the company, valued at $6,369,303.65. This represents a 3.81 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,197 shares of company stock valued at $315,310. Insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.